A STUDY OF ASP2215 (GILTERITINIB) BY ITSELF, ASP2215 COMBINED WITH AZACITIDINE OR AZACITIDINE BY ITSELF TO TREAT ADULT PATIENTS WHO HAVE RECENTLY BEEN DIAGNOSED WITH ACUTE MYELOID LEUKEMIA WITH A FLT3 GENE MUTATION AND WHO CANNOT RECEIVE STANDARD CHEMOTHERAPY: